Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. (NASDAQ: MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer, and its news flow reflects both scientific progress and commercial execution. Company updates frequently highlight developments around its flagship colorectal cancer screening test, ColoAlert, and its pancreatic cancer screening program, including PancAlert and related biomarker studies.
Investors and observers following MYNZ news can expect announcements on regulatory milestones, such as registrations and approvals that enable ColoAlert to be marketed in additional countries, as well as commercial partnerships with diagnostic laboratories, distributors, and digital health platforms. Examples include agreements to launch ColoAlert in Switzerland through a local laboratory partner, collaborations to introduce the test in South America, and inclusion of ColoAlert in digital preventive healthcare offerings in Germany.
News items also cover Mainz Biomed’s clinical development activities. These include updates on the eAArly DETECT and eAArly DETECT 2 studies for next generation colorectal cancer testing, presentations of clinical data on RNA‑based screening at international meetings, and feasibility and verification studies for blood‑based pancreatic cancer screening using licensed mRNA biomarkers and AI‑assisted algorithms. The company regularly announces participation in major conferences such as the American Association for Cancer Research Annual Meeting, MEDICA, and colorectal cancer screening committees organized by professional societies.
In addition, MYNZ news may include capital markets disclosures, such as securities purchase agreements, equity distribution arrangements, and summaries of financial reports filed on Form 6‑K. For readers seeking a consolidated view of these developments, this page provides a chronological feed of press releases and regulatory news that illustrate how Mainz Biomed is advancing its molecular diagnostic products, expanding market access, and managing its financing activities. Regular visits can help track scientific milestones, geographic expansion of ColoAlert, and progress in the company’s pancreatic cancer program.
Mainz Biomed (NASDAQ:MYNZ) reported topline feasibility results for a non-invasive, blood-based pancreatic cancer screening test using 18 licensed biomarkers. In a 30-subject cohort the leading panel achieved 100% sensitivity and 95% specificity, and the algorithm also detected precancerous lesions. These results align with earlier discovery/validation datasets that showed 95% sensitivity and 98% specificity. Mainz Biomed will plan a larger confirmatory study using banked retrospective samples, then a PCR-based validation study and potential future FDA submission, pending outcomes.
Mainz Biomed (NASDAQ:MYNZ) will present groundbreaking clinical data from their eAArly DETECT study at the World Endoscopy Organization's CRC Screening Committee Meeting on October 3rd, 2025 in Berlin.
Dr. Lena Krammes will showcase the company's RNA-based diagnostic test results, which demonstrated remarkable efficacy with 97% sensitivity and specificity for colorectal cancer detection, 82% sensitivity for advanced adenomas, and 100% detection rate for advanced adenomas with high-grade dysplasia.
The presentation, titled "From Detection to Prevention," will highlight the potential of stool RNA testing in both early cancer detection and prevention through identification of high-risk lesions.
Mainz Biomed (NASDAQ:MYNZ) has announced the commercial launch of its flagship product ColoAlert® in Switzerland, marking a significant expansion of its colorectal cancer screening solution. The launch follows three key achievements: a strategic partnership with labor team w ag, one of Switzerland's leading diagnostic laboratories; regulatory approval from Swissmedic; and successful completion of technology transfer to labor team's facility in Goldach.
Additionally, the company provided an update on its eAArly DETECT 2 Study, which aims to enroll 2,000 average-risk patients. Management has decided to proceed with complete enrollment through the end of 2025 without pausing for an interim readout.
Mainz Biomed (NASDAQ:MYNZ) has achieved a significant milestone with the registration of ColoAlert®, its DNA-based colorectal cancer screening test, by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This regulatory approval enables marketing authorization across the United Kingdom.
The registration follows Mainz's technology partnership with EDX Medical Group plc and aims to address the UK's colorectal cancer burden, where approximately 44,000 new cases are diagnosed annually. ColoAlert will complement the existing Bowel Cancer Screening Program, which currently serves people aged 50-74, by providing a non-invasive screening option that detects DNA biomarkers in stool samples.
Mainz Biomed (NASDAQ:MYNZ) has received regulatory approval from Swissmedic to market ColoAlert®, its non-invasive colorectal cancer screening test, in Switzerland. The approval follows the company's partnership with labor team w ag, a local Swiss laboratory.
The Swiss market represents a significant opportunity, with 2.8 million people (31.4% of the population) in the target age group of 50-74 years. Current colorectal cancer screening participation rates in Switzerland are below 50% despite having over 13 screening programs nationwide. ColoAlert®, designed to detect CRC tumor DNA and other biomarkers in stool samples, aims to improve these participation rates.
Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has announced the pricing of a $3.0 million follow-on offering. The offering consists of 2,222,222 units priced at $1.35 per unit, with each unit including one ordinary share (or pre-funded warrant) and one Series A warrant.
The Series A warrants will be immediately exercisable at $1.35 per share with a five-year expiration term. Maxim Group LLC serves as the sole placement agent, with the offering expected to close around August 5, 2025, subject to customary conditions.
Mainz Biomed (NASDAQ:MYNZ) has announced a strategic collaboration with CARE diagnostica Laborreagenzien GmbH to expand colorectal cancer screening services in Germany. The partnership will integrate Mainz Biomed's ColoAlert® test into CARE's existing screening programs, which currently serve more than 15 statutory health insurance companies.
The collaboration enables CARE to enhance its screening offerings by incorporating ColoAlert®'s molecular genetic analysis capabilities, which use PCR to analyze biomarkers in stool samples. This advanced technology aims to improve early-stage detection rates compared to traditional fecal immunochemical tests (FIT).
Mainz Biomed (NASDAQ:MYNZ) reported significant progress in H1 2025, focusing on advancing its colorectal and pancreatic cancer screening technologies. The company launched eAArly DETECT 2, a US feasibility study evaluating its next-gen colorectal cancer test across 2,000 average-risk patients.
A key development was the License and Option Agreement with Liquid Biosciences for pancreatic cancer screening biomarkers, which demonstrated 95% sensitivity and 98% specificity in initial studies. The company secured public funding from ISB for up to 50% of the pancreatic cancer project costs.
Additionally, Mainz Biomed expanded its market presence through partnerships with labor team w ag in Switzerland and EDX Medical Group in the UK. The company also completed a $4.0 million follow-on offering and regained full Nasdaq compliance.
Mainz Biomed (NASDAQ:MYNZ) has secured significant public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer screening test development. The ISB will fund up to 50% of the total project costs through its Innovation and Technology Support Program.
The company is currently in the feasibility phase, collaborating with Crown Bioscience to evaluate a panel of mRNA biomarkers and a machine learning-driven algorithm using clinical blood samples. This non-invasive, blood-based screening test aims to enable earlier detection of pancreatic cancer, potentially improving treatment outcomes.